CryoLife is one of the world’s contemporary medical device companies providing preserved human cardiac and vascular tissues, surgical adhesives and sealants, cardiac lasers and implantable end-stage renal disease access grafts for the repair of complex cardiac and vascular reconstruction surgeries. 
CryoLife using its proprietary SynerGraft technology processes the CryoValve SG pulmonary heart valve and CryoPatch SG pulmonary cardiac patch. CryoLife’s CardioGenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR). CryoLife markets the HeRO Graft, which provides vascular access for hemodialysis patients. CryoLife distributes PerClot, an absorbable powdered hemostat, in international markets. CryoLife’s BioFoam Surgical Matrix is CE marked in the European Community for use as an adjunct to hemostasis.

Company Growth (employees)
Kennesaw, US
Size (employees)
665 (est)
CryoLife was founded in 1984 and is headquartered in Kennesaw, US

Key People/Management at CryoLife

Thomas F. Ackerman

Thomas F. Ackerman

Member of the Board

CryoLife Office Locations

CryoLife has offices in Kennesaw, Guildford, Freiburg im Breisgau, Singapore and in 1 other location
Kennesaw, US (HQ)
1655 Roberts Blvd
Paris, FR
52 Rue de la Victoire
Freiburg im Breisgau, DE
19 Engelbergerstraße
Singapore, SG
1 Marina Blvd
Guildford, GB
Old Portsmouth Rd
Show all (5)

CryoLife Financials and Metrics

CryoLife Financials

CryoLife's revenue was reported to be $180.4 m in FY, 2016

Revenue (Q3, 2017)

44 m

Net income (Q3, 2017)

1.3 m

EBIT (Q3, 2017)

829 k

Market capitalization (22-Dec-2017)

660.7 m

Cash (30-Sep-2017)

54.2 m


674.5 m
CryoLife's current market capitalization is $660.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


140.8 m144.6 m145.9 m180.4 m

Revenue growth, %


R&D expense

13.4 m

Operating expense total

13.4 m
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


43 m47.1 b45.3 m45.1 m47.8 m44 m

R&D expense

2.6 m3.3 b3.7 m4.1 m4.7 m4.3 m

Operating expense total

28.9 m25.7 b24.3 m27 m28.1 m29 m


6.7 m4.6 b5.5 m2.5 m4.8 m829 k
USDFY, 2013FY, 2014FY, 2015FY, 2016


37.6 m33.4 m37.6 m56.6 m

Accounts Receivable

136.7 m


9.8 m12.7 m14.6 m26.3 m

Current Assets

106.3 m106 m109.7 m147.2 m
USDQ1, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


32.8 m44.8 m46.9 m54.1 m58.9 m52.5 m54.2 m


11.5 m25.3 m25.4 m25.5 m25.8 m26.5 m27.8 m

Current Assets

105.9 m129.2 m135.8 m142.1 m149.2 m152.2 m155.6 m


12 m16.5 m16.4 m17.2 m20.2 m20.7 m20.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

16.2 m7.3 m4 b10.8 m

Depreciation and Amortization

5.8 m6 m5.9 b8.4 m

Cash From Operating Activities

24.6 m(4.3 m)4.2 m

Capital Expenditures

(4.3 m)(4.3 m)(3.5 b)(6.2 m)
USDQ1, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

1.1 m2.5 m4.9 m7.9 m2.2 m5.4 m6.7 m

Depreciation and Amortization

1.5 m1.9 m4.1 m6.2 m2.2 m4.4 m6.7 m

Capital Expenditures

(1 m)(820 k)(1.6 m)(3.5 m)(2 m)(4.3 m)(5.4 m)

Cash From Investing Activities

(1.7 m)(67.2 m)(69.2 m)(71.1 m)(1.2 m)(3.6 m)(4.6 m)
USDY, 2017


813.7 x


66.2 k

Financial Leverage

1.5 x
Show all financial metrics

CryoLife Market Value History

CryoLife's Web-traffic and Trends

CryoLife Online and Social Media Presence

CryoLife Company Life and Culture

You may also be interested in